Price$2.25+0.26 (+13.35%)
2026-01-212026-04-24
News · 26 weeks160%
2025-11-022026-04-26
Mix390d
- SEC Filings2(67%)
- Other1(33%)
Latest news
25 items- SECAmendment: SEC Form 10-K/A filed by Creative Medical Technology Holdings Inc.10-K/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- SECSEC Form 10-K filed by Creative Medical Technology Holdings Inc.10-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- PRCreative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy PipelinePHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide. The WHO has published the proposed INN "etaroleucel" for CELZ-101, the Company's autologous regulatory T-cell (Treg) i
- PRCreative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back PainPHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company's proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease. The study produced statistically significant, clinically meaningful improvements in both functional disability (ODI%) and pain at primary trial end point, confirming durable human efficacy alongside an excelle
- PRCreative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit InitiativePHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today announced that its BioDefense Inc. Burn Pit Initiative has received regulatory approval to proceed, marking a significant milestone in the Company's mission to address the long-term health consequences of toxic burn pit exposure among U.S. military veterans. Importantly, the Company also confirmed that no additional fundraising is required to execute this initiative, as the program will be supported through existing strategic partnerships,
- SECCreative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- SECCreative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- PRCreative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection PointPHOENIX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the successful completion of patient enrollment in its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company's proprietary perinatal tissue-derived cell therapy for the treatment of chronic lower back pain associated with degenerative disc disease. Enrollment completion follows a previously announced positive independent Data Safety Monitoring Board (DSMB) safety review, which confirmed that CELZ-201 demonstrated a favorable safety profile with no significant adverse e
- SECSEC Form 424B3 filed by Creative Medical Technology Holdings Inc.424B3 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- SECSEC Form EFFECT filed by Creative Medical Technology Holdings Inc.EFFECT - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- PRCreative Medical Technology Holdings Announces World Health Organization Approval of "olastrocel" as INN for Lead Allogeneic Cell Therapy CELZ-201PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced that the World Health Organization (WHO) has approved "olastrocel" as the International Non-Proprietary Name (INN) for the active cellular substance in CELZ-201, the Company's lead allogeneic cell therapy also known as AlloStem®. The INN is the globally standardized, unique scientific name used by regulators, clinicians, researchers, and global markets to identify a therapeutic substance throughout its development and commercializat
- SECSEC Form S-3 filed by Creative Medical Technology Holdings Inc.S-3 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- SECSEC Form DEF 14A filed by Creative Medical Technology Holdings Inc.DEF 14A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- SECCreative Medical Technology Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- SECSEC Form 10-Q filed by Creative Medical Technology Holdings Inc.10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- SECSEC Form PRE 14A filed by Creative Medical Technology Holdings Inc.PRE 14A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- SECCreative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- PRCreative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn PitsPHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage leader in regenerative and cellular innovation, today announced the official launch of its BioDefense Inc. Veterans Initiative, believed to be a first-of-its-kind national program to combat the devastating long-term effects of toxic burn pit exposure among U.S. service members. This initiative underscores the Company's commitment to establishing a mission-critical role in America's biodefense infrastructure by positioning Creative Medical as a cornerstone of national medical readiness and veteran health security. The program will utili
- SECSEC Form DEF 14A filed by Creative Medical Technology Holdings Inc.DEF 14A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- PRCreative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross ProceedsPHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.75 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-286346). The aggregate
- PRCreative Medical Technology Holdings Issues Letter to ShareholdersPHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Company's history, we have evolved from proof-of-concept to clinical trials in support of our mission to develop breakthrough regenerative stem cell therapies across multiple indications. At the
- PRCreative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell BreakthroughsPHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work—including the identification of Tregs and the central role of FOXP3—reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer. In parallel wi
- PRCreative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back PainPHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability. This designation positions CELZ-201-DDT among a select group of therapies recognized for their potential to address serious medical conditions with high unmet need. Fast Track status enables the Company to benefit from accelerated FDA int
- SECSEC Form 10-Q filed by Creative Medical Technology Holdings Inc.10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
- PRCreative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune CellsPHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, "Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity." Once granted, the patent will be in effect until at least 2040. The patent allows a broad cell-based immunotherapy approach to treating Type 1 diabetes using the ImmCelzTM product, which includes the supercharged T
CELZ FAQ
6 questionsWhat does Creative Medical Technology Holdings Inc. do?
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and...Where does CELZ stock trade?
Creative Medical Technology Holdings Inc. (CELZ) is listed on NASDAQ.What sector and industry is CELZ in?
Creative Medical Technology Holdings Inc. operates in the Finance sector, Finance: Consumer Services industry.What are analysts saying about CELZ?
Creative Medical Technology Holdings Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1000.00 price target on 2022-02-25. Recent price targets cluster around $1000.00.What companies are similar to CELZ?
Notable peers in the same industry include AXP (American Express Company), SPGI (S&P Global Inc.), MCO (Moody's Corporation), NU (Nu Holdings Ltd.), COIN (Coinbase Global Inc.). Compare CELZ side-by-side with any of them on Quantisnow.How can I track CELZ on Quantisnow?
Quantisnow aggregates Creative Medical Technology Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CELZ to receive live email and push alerts on every new disclosure.